⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 8, 2024Open Access

Figure S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors

Caroline E. Dravillas Samuel S. Coleman Rebecca Hoyd Griffin Caryotakis Louis Denko Carlos H.F. Chan Michelle L. Churchman Nicholas Denko Rebecca D. Dodd Islam Eljilany Sheetal Hardikar Marium Husain Alexandra P. Ikeguchi Ning Jin Qin Ma Martin D. McCarter Afaf E.G. Osman Lary A. Robinson Eric A. Singer Gabriel Tinoco Cornelia M. Ulrich Yousef Zakharia Daniel Spakowicz Ahmad A. Tarhini Aik Choon Tan

View Full Paper

Ask AI

Bookmark

Share

Abstract

Predictive values (AUROC) of the 16 gene signatures in the ORIEN cohort (IO_NOVA_Mel) and 22 other melanoma cohorts

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dravillas et al. (2024) studied this question.

synapsesocial.com/papers/68e5d11bb6db643587567536 https://doi.org/10.1158/2767-9764.26519611.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
2Table S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
3Table S3 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
4Figure 5 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
5Figure 4 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024

More related papers

Table S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
Table S1 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024
Figure 6 from The Tumor Microbiome as a Predictor of Outcomes in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors2024